RFG Advisory LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

RFG Advisory LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 35.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 66,463 shares of the biopharmaceutical company’s stock after selling 35,816 shares during the period. RFG Advisory LLC’s holdings in Pfizer were worth $1,860,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Wellington Management Group LLP lifted its stake in shares of Pfizer by 4.9% during the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after acquiring an additional 11,099,024 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 8.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock valued at $2,985,783,000 after purchasing an additional 8,473,686 shares during the period. Norges Bank bought a new position in shares of Pfizer in the fourth quarter worth about $2,129,927,000. Massachusetts Financial Services Co. MA increased its stake in Pfizer by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock worth $1,972,300,000 after buying an additional 8,298,920 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Pfizer by 21.8% during the 1st quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock valued at $438,820,000 after buying an additional 2,829,178 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE stock traded down $0.10 during mid-day trading on Monday, reaching $28.45. 21,118,387 shares of the company’s stock were exchanged, compared to its average volume of 39,683,160. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.78. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.19. The stock’s 50 day moving average is $28.80 and its 200 day moving average is $27.86. The company has a market cap of $161.21 billion, a price-to-earnings ratio of -475.59, a price-to-earnings-growth ratio of 1.02 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. On average, research analysts expect that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.91%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Ratings Changes

Several research analysts recently issued reports on PFE shares. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.